Cystic fibrosis and COVID: are patients naturally protected?

NCT ID NCT04992234

Completed Knowledge-focused Sponsor: Vastra Gotaland Region Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 113 people with cystic fibrosis (CF) over two years to see how many developed antibodies against COVID-19, either from infection or vaccination. Researchers collected blood samples and health data to understand if CF patients have a lower infection rate and how their immune system responds. The goal is to learn more about COVID-19 in this specific group, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could clarify why people with cystic fibrosis seem to have fewer COVID-19 cases and how their immune system responds to the virus and vaccines.
What could go wrong: This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all people with cystic fibrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 CYSTIC FIBROSIS

Contacts and locations

Locations

Karolinska University Hospital

Huddinge, Sweden
Sahlgrenska University Hospital

Gothenburg, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.